Patents by Inventor Cindy Luongo

Cindy Luongo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant respiratory syncytial virus strains with mutations in the M2-2 ORF providing a range of attenuation phenotypes
    Patent number: 11332721
    Abstract: Provided herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype that contain mutations in the M2-2 open reading frame that interfere with the expression of the M2-2 protein. The M2-2 mutations may be present in combination with mutations at other loci. Using methods described herein, combinations of mutations are provided to achieve desired levels of attenuation. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences of the described viruses, as well as methods for producing and using the viruses.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: May 17, 2022
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter L. Collins, Ursula J. Buchholz, Cindy Luongo
  • RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS STRAINS WITH MUTATIONS IN THE M2-2 ORF PROVIDING A RANGE OF ATTENUATION PHENOTYPES
    Publication number: 20200283740
    Abstract: Provided herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype that contain mutations in the M2-2 open reading frame that interfere with the expression of the M2-2 protein. The M2-2 mutations may be present in combination with mutations at other loci. Using methods described herein, combinations of mutations are provided to achieve desired levels of attenuation. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences of the described viruses, as well as methods for producing and using the viruses.
    Type: Application
    Filed: May 18, 2020
    Publication date: September 10, 2020
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter L. Collins, Ursula J. Buchholz, Cindy Luongo
  • Recombinant respiratory syncytial virus stains with mutations in the M2-2 ORF providing a range of attenuation phenotypes
    Patent number: 10655109
    Abstract: Provided herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype that contain mutations in the M2-2 open reading frame that interfere with the expression of the M2-2 protein. The M2-2 mutations may be present in combination with mutations at other loci. Using methods described herein, combinations of mutations are provided to achieve desired levels of attenuation. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences of the described viruses, as well as methods for producing and using the viruses.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: May 19, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter L. Collins, Ursula J. Buchholz, Cindy Luongo
  • RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS STRAINS WITH MUTATIONS IN THE M2-2 ORF PROVIDING A RANGE OF ATTENUATION PHENOTYPES
    Publication number: 20190040365
    Abstract: Provided herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype that contain mutations in the M2-2 open reading frame that interfere with the expression of the M2-2 protein. The M2-2 mutations may be present in combination with mutations at other loci. Using methods described herein, combinations of mutations are provided to achieve desired levels of attenuation. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences of the described viruses, as well as methods for producing and using the viruses.
    Type: Application
    Filed: December 12, 2016
    Publication date: February 7, 2019
    Inventors: Peter L. Collins, Ursula J. Buchholz, Cindy Luongo